BioRestorative Therapies
NASDAQ: BRTXMelville, US · Nevada corporation
Find your way into BioRestorative Therapies
373 people in our graph share verified history with the BioRestorative Therapies team — schools, employers, funds. One of them is your warm intro.
BioRestorative Therapies develops cell-based therapeutic products using adult stem cells, primarily for treating disc and spine disorders and metabolic conditions, and operates a commercial cosmetic serum product. The company's lead program, BRTX-100, is an autologous mesenchymal stem cell therapy in Phase 2 clinical trials for chronic lower back pain and cervical disc disease, while its ThermoStem program targets obesity and metabolic disorders using brown adipose tissue-derived stem cells.
Founders & leadership
Board
Reported raises · per SEC filings
Form D private placements$16.4M disclosed across 3 rounds · 2013–2025
▶$1.4MraisedOct 2025 · 16 investors · BiotechnologyRule 506(b)
- Nickolay V KukekovDirector
- Robert KristalExecutive Officer
- Francisco SilvaDirector, Executive Officer
- Patrick F WilliamsDirector
- David A RosaDirector
- Lance AlstodtDirector, Executive Officer
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- Placement agents
- Cova Capital Partners LLC
- First sale
- Oct 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$14.4MraisedMay 2016 · 81 investors · BiotechnologyRule 506(b)
- Edward L. FieldExecutive Officer
- Francisco SilvaExecutive Officer
- Paul Jude TonnaDirector
- Robert B. CatellDirector
- A. Jeffrey RadovDirector
- John M. DesmaraisDirector
- Charles S. RyanDirector
- Mandy ClydeExecutive Officer
- Mark WeinrebExecutive Officer, Director
- Amount sold
- $14.4M
- Proceeds to insiders
- $2.7M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$585.8KraisedMar 2014 · 21 investors · BiotechnologyRule 506(b)
- Mandy ClydeExecutive Officer
- Mark WeinrebExecutive Officer, Director
- Tommy BergerPromoter
- Francisco SilvaExecutive Officer
- Gloria McConnellPromoter
- A. Jeffrey RadovDirector
- Joel San AntonioDirector
- Offering amount
- $1.2M
- Amount sold
- $585.8K
- Proceeds to insiders
- $117K
- First sale
- Dec 2013
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $256.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $256.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
BioRestorative Therapies (NASDAQ:BRTX): What Could Today's Update Reveal About Healthcare Execution?kalkinemedia.com · Aug 2026Frequently asked questions
- What does BioRestorative Therapies do?
- BioRestorative Therapies develops cell-based therapeutic products using adult stem cells, primarily for treating disc and spine disorders and metabolic conditions, and operates a commercial cosmetic serum product. The company's lead program, BRTX-100, is an autologous mesenchymal stem cell therapy in Phase 2 clinical trials for chronic lower back pain and cervical disc disease, while its ThermoStem program targets obesity and metabolic disorders using brown adipose tissue-derived stem cells.
- Who founded BioRestorative Therapies?
- BioRestorative Therapies was founded by Mark Weinreb.
- How much funding has BioRestorative Therapies raised?
- BioRestorative Therapies has disclosed $16.4M raised across 3 rounds.
- Where is BioRestorative Therapies headquartered?
- BioRestorative Therapies is headquartered in Melville, US.